Diabetes, Vol 44, Issue 6 626-630, Copyright © 1995 by American Diabetes Association

ARTICLES

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM

J Dupre, MT Behme, IM Hramiak, P McFarlane, MP Williamson, P Zabel and TJ McDonald
Department of Medicine, University of Western Ontario, London, Canada.

Effects of human glucagon-like peptide I (GLP-I)(7-36)amide were examined in volunteers having insulin-dependent diabetes mellitus (IDDM) with residual C-peptide (CP) secretion (n = 8, 7 men and 1 woman; age, 31 +/- 1.4 years; body mass index, 24.7 +/- 0.7 kg/m2; duration of diabetes, 3.2 +/- 0.8 years; insulin dose, 0.41 +/- 0.05 U.kg-1.day-1; meal-stimulated CP, 1.0 +/- 0.2 nmol/l [means +/- SE]). After a mixed meal (Sustacal, 30 kJ/kg body wt), intravenous injection of GLP-I, 1.2 pmol.kg-1.min-1 through 120 min, virtually abolished increments of plasma glucose, CP, pancreatic polypeptide (PP), and glucagon concentrations, with no significant effect on plasma gastrin levels during the infusions. At reduced dosage (0.75 pmol.kg-1.min-1), GLP-I had lesser effects on plasma glucose and CP levels. On cessation of intravenous GLP-I infusions after the meals, plasma glucose, CP, PP, and glucagon concentrations rebounded toward control levels by 180 min, and the response of plasma gastrin was prolonged. These rebound responses are consistent with intestinal delivery of food retained in the stomach on escape from inhibition of gastric emptying by GLP-I. Infusion of 1.2 pmol.kg-1.min-1 GLP-I with 20 g glucose (10% dextrose in water) injected intravenously over 60 min enhanced plasma responses of immunoreactive CP; the mean incremental areas under concentration curves (0-60 min) increased sixfold, but the glycemic excursion was not affected. Thus, in CP-positive IDDM, pharmacological doses of GLP-I reduce glycemic excursions after meals by a mechanism(s) not dependent on stimulation of insulin secretion, presumably involving delayed gastric emptying.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. E. Ayala, D. P. Bracy, T. Hansotia, G. Flock, Y. Seino, D. H. Wasserman, and D. J. Drucker Insulin Action in the Double Incretin Receptor Knockout Mouse Diabetes, February 1, 2008; 57(2): 288 - 297. [Abstract] [Full Text] [PDF]

				N. A. Sherry, W. Chen, J. A. Kushner, M. Glandt, Q. Tang, S. Tsai, P. Santamaria, J. A. Bluestone, A.-M. B. Brillantes, and K. C. Herold Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of {beta}-Cells Endocrinology, November 1, 2007; 148(11): 5136 - 5144. [Abstract] [Full Text] [PDF]

				J. Dupre, M. T. Behme, and T. J. McDonald Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3469 - 3473. [Abstract] [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]

				G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, M. R.W. Ehlers, J. M. Egan, and D. Elahi Effect of Glucagon-Like Peptide 1 (7-36 Amide) on Insulin-Mediated Glucose Uptake in Patients With Type 1 Diabetes Diabetes Care, March 1, 2003; 26(3): 837 - 842. [Abstract] [Full Text] [PDF]

				J. A. Pospisilik, J. Martin, T. Doty, J. A. Ehses, N. Pamir, F. C. Lynn, S. Piteau, H.-U. Demuth, C. H.S. McIntosh, and R. A. Pederson Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates {beta}-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats Diabetes, March 1, 2003; 52(3): 741 - 750. [Abstract] [Full Text] [PDF]

				A. Vella, P. Shah, R. Basu, A. Basu, M. Camilleri, F. W. Schwenk, J. J. Holst, and R. A. Rizza Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes Diabetes, March 1, 2001; 50(3): 565 - 572. [Abstract] [Full Text]

				J Schirra, P Houck, U Wank, R Arnold, B Goke, and M Katschinski Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans Gut, May 1, 2000; 46(5): 622 - 631. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				A. S. Ryan, J. M. Egan, J. F. Habener, and D. Elahi Insulinotropic Hormone Glucagon-Like Peptide-1-(7-37) Appears Not to Augment Insulin-Mediated Glucose Uptake in Young Men during Euglycemia J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2399 - 2404. [Abstract] [Full Text]

				M. A. Nauck, U. Niedereichholz, R. Ettler, J. J. Holst, C. Orskov, R. Ritzel, and W. H. Schmiegel Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E981 - E988. [Abstract] [Full Text] [PDF]